Literature DB >> 238782

Disposition of acetylmethadol in relation to pharmacologic action.

R F Kaiko, C E Inturrisi.   

Abstract

The levels of acetylmethadol and its active biotransformation products were quantitated in the plasma and urine of subjects on acetylmethadol maintenance by the use of solvent extraction and gas-liquid chromatography. The time-course of plasma acetylmethadol, noracetylmethadol, and dinoracetylmethadol over 48 hr was determined concurrently with the time-action of pupillary constriction in 8 subjects receiving an average oral maintenance dose of 50 mg. The plasma level of acetylmethadol reached a peak at 4 hr and had nearly disappeared by 24 hr. The mean apparent half-life was 7 hr. The plasma level of noracetylmethadol peaked at 4 to 8 hr and slowly declined over the next 40 hr. The mean apparent half-life of noracetylmethadol was 48 hr. Dinoracetylmethadol plasma levels remained relatively constant throughout the dosing interval. The miotic effect reached a peak at 8 hr and decayed at a rate slower than that of plasma elimination of acetylmethadol but more rapidly than that of noracetylmethadol and dinoracetylmethadol. Substantial variation in the plasma levels of the compounds was observed in subjects after the same doses. The study indicated that the relatively long duration of opiate effects of acetylmethadol results from biotransformation to active and persistent metabolites.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 238782     DOI: 10.1002/cpt197518196

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Authors:  Evan D Kharasch; Dale Whittington; Christine Hoffer; Kevin Krudys; Keith Craig; Paolo Vicini; Pam Sheffels; Bojan Lalovic
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Blood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparation.

Authors:  David J R Foster; Mette L Jensen; Richard N Upton; Andrew A Somogyi; Cliff Grant; Allison Martinez
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  Modern opioids: uses defined by chrono-pharmacology, not receptor selectivity.

Authors:  A W Fox
Journal:  J R Soc Med       Date:  1995-09       Impact factor: 5.344

Review 4.  Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.

Authors:  D E Drayer
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

5.  Methadone and methadone metabolites in postmortem specimens.

Authors:  Terry J Danielson; Ashraf Mozayani; Luis A Sanchez
Journal:  Forensic Sci Med Pathol       Date:  2008-05-30       Impact factor: 2.007

Review 6.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

7.  Effects of levo-alpha-acetylmethadol (LAAM) on morphine self-administration in the rat.

Authors:  S E Lukas; J E Moreton; N Khazan
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.